glipizide + metformin

**Glipizide + metformin** is an oral fixed-dose antidiabetic combination for **type 2 diabetes mellitus**. It combines glipizide, a sulfonylurea that binds the pancreatic beta-cell sulfonylurea receptor 1 and closes ATP-sensitive potassium channels to stimulate insulin secretion, with metformin, a biguanide that principally reduces hepatic glucose production and improves insulin sensitivity. The complementary actions improve glycemic control when diet and exercise alone are insufficient. The original US branded product was **Metaglip**, developed by Bristol Myers Squibb; generic immediate-release tablets are available. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021460s010lbl.pdf))

Brand names

Metaglip

Other names

glipizide + metforminglipizide and metforminglipizide/metforminglipizide/metformin hydrochloride